logo-loader

Beaufort Securities Breakfast Alert: Motif Bio Plc, Tissue Regenix Group PLC

Published: 03:32 05 Jun 2017 EDT

no_picture_pai

Today's edition features:

• Motif Bio (LON:MTFB)

• Tissue Regenix Group (LON:TRX)

 

US interest rate prospects moderating

"The big news from the US on Friday was the large drop in the May Non-farm payroll number to a gain of just 138,000 against the widely-expected 185,000. At 4.3%, the unemployment rate hit a 16-year low but the underlying message was of a slowing economy. Consequently, the outlook for the trend in future interest rates has turned softer. However, despite this dip towards a more typical jobs growth rate, it is still widely expected that at the US Federal Reserve's next FOMC meeting on the 14th June will produce another 25-basis point rise. A question mark is raised though over the outlook for the rest of the year, particularly September, for any other rate rises. Inevitably, the US bond market yields eased in line with the implied lower rate trajectory while the Dollar also lost ground.

President Trump's decision to drop out of the Paris Accord on Climate Change left the price of crude oil below $50 pb on the prospect of increased US oil production. The President argues that the terms agreed by the Obama Administration discriminate against the US and it should be expected that Trump will attempt to negotiate a better deal at some stage. This is to be hoped for since some of the thinking behind the decision to leave looks a little flawed.

On the UK General Election trail, the tragic terrorist attacks on Saturday night might have been expected to provide political ammunition to opposition parties around the adequacy of current security measures and the level of investment. Whilst the facts may not be allowed to interfere with a good sound bite against the Tory Party, it does appear that the police rapid-response units were well-prepared, with the attackers being dealt with just 8 minutes after the first alert went out. After yet another temporary suspension of electioneering, there are now just three more days of campaigning left to the parties until Polling Day. As might be assumed, weekend press comment highlights the likely risk to Sterling from a Labour Party victory or a Labour-SNP alliance, as we indicated last week."

- Mike Franklin, Chief Investment Strategist

 

Markets

Europe

The FTSE-100 finished Friday's session 0.05% higher at 7,547.63 whilst the FTSE AIM All-Share index was up 0.10% at 991.80. In continental Europe, the CAC-40 finished up 0.47% at 5,343.41 whilst the DAX was 1.25% higher at 12,822.90.

Wall Street

In New York on Friday night, the Dow Jones rose 0.29% to 21,206.29, the S&P-500 firmed 0.37% to 2,439.07 and the Nasdaq gained 0.94% to stand at 6,305.8.

Asia

In Asian markets this morning, the Nikkei 225 had fallen about 0.0% to 20,176.99, while the Hang Seng slipped 0.33% to 25,838.21.

Oil

In early trade today, WTI crude was up 1.36% to $48.31/bbl and Brent was up 1.36% to $50.63/bbl.

 

Headlines

London attack: PM's condemnation of tech firms criticised

Prime Minister Theresa May has been warned that her promise to tighten regulation on tech firms after the London attacks will not work. Mrs May said areas of the internet must be closed because tech giants provided a "safe space" for terrorist ideology. But the Open Rights Group said social media firms were not the problem, while an expert in radicalisation branded her criticism "intellectually lazy". Twitter, Facebook and Google said they were working hard to fight extremism. Google (which owns Youtube), Facebook (which owns WhatsApp) and Twitter were among tech companies already facing pressure to tackle extremist content - pressure that intensified on Sunday. Mrs May said: "We cannot allow this ideology the safe space it needs to breed. "Yet that is precisely what the internet, and the big companies... provide."

Source: BBC News

 

Company news

Motif Bio (LON:MTFB, 33.75p) – Speculative Buy

Motif Bio, the AIM and NASDAQ-quoted clinical stage biopharmaceutical company specialising in developing novel antibiotics, on Friday announced that it has successfully raised £20.0m (US$25.8m) by way of an issue of 66,666,667 new ordinary shares to both new and existing investors at the placing price of 30p. The placing shares will represent 34% of the issued ordinary share capital of the Company prior to the placing. The Placing Price represents a discount of 11.7% to the trailing ten day VWAP of 34p and a discount of 21.1% to the Company's mid-market closing price as at 1 June 2017. The placing remains conditional, inter alia, on the passing of certain resolutions by shareholders of the Company at a general meeting expected to be held on 22 June 2017. Upon approval, application is expected to be made for the new placing shares to be admitted to trading on AIM at 8.00 am on 23 June 2017. The new placing shares will rank pari passu with the Company's existing Ordinary Shares. Motif Bio's CEO, Graham Lumsden, commented "This financing has been well received and gives us the resources to complete the REVIVE-2 Phase 3 clinical trial and file a New Drug Application and Marketing Authorisation Application in the first half of 2018 to achieve marketing approval of iclaprim in the US and Europe. I am delighted by the support shown by our existing shareholders and also welcome a number of new institutional holders to the register".

Our view: Clouds are rapidly disappearing! Motif Bio has now secured necessary funding to complete its Phase III REVIVE-2 study for treatment of acute bacterial skin and skin structure infections ('ABSSSI'). Subject to shareholder approval, the total raise of £20.0m (US$25.8m), before expenses, will take Motif to submission of NDA (FDA) and a MAA (EMA) for its novel antibiotic candidate, iclaprim, in ABSSSI, while also provide funding for general corporate purposes. Iclaprim appears capable of creating considerable value for Motif shareholders, as seen back in 18 April 2017, where the Group announced a positive Phase III Topline Results for iclaprim in REVIVE-1 for treatment of ABSSSI. Motif is currently working on REVIVE-2, its second Phase III ABSSSI trial, which more than 80% of the total patients has now enrolled. The Board is increasingly confident as REVIVE-2 uses an identical protocol to REVIVE-1 at different trial centres. Topline Data for REVIVE-2 is expected in the H2 2017. Assuming positive results for REVIVE-2, together with REVIVE-1, this will comprise sufficient regulatory data to complete NDA submissions to both the FDA and EMA early in H1 2018. Unlike current standard of care antibiotics, in clinical trials to date, nephrotoxicity has not been observed with iclaprim and dosage adjustment has not been required in renally impaired patients. This is important, given that it is estimated that up to 26% of the 3.6 million ABSSSI patients hospitalised annually in the US have kidney disease. This suggests very significant prospective demand for this novel antibiotic. Moreover, preparations are now completed for INSPIRE, the Phase III trial designed to study the safety and efficacy of iclaprim in patients with hospital acquired bacterial pneumonia ('HABP'), including ventilator associated bacterial pneumonia (VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus). Beaufort considers this platform antibiotic could achieve a value in excess of US$1bn following successful commercialisation of just the molecule's first two indications. Now that funding gap being fulfilled, with Motif's market capitalisation of just £65m against its most obvious comparative, Paratek Pharmaceuticals' US$567m, the giant valuation gap with its peer could rapidly close. Beaufort reiterate its Speculative Buy rating with a target price of 110p. Motif Bio is one of Beaufort's Tips for 2017.

 

Tissue Regenix Group (LON:TRX, 15.50p) – Hold

Tissue Regenix Group, the regenerative medical devices company, on Friday announced its annual results for the 11 months ended 31 December 2016 ('FY2016'). The period comprised of 11 months due to change in accounting reference period to a December year end. During the period, revenue advanced by +77% to £1.4m, against the comparative period (FY2015), primarily driven by +64% increase in sale of DermaPure to £1.3m, together with first revenue contribution from its controlled German Joint Venture, GBM-V. An increased investment in sales and marketing has led to an operational loss of £11.1m (FY2015: 10.2m), result in loss for the year of £9.9m (FY2015: £9.5m) and basic loss per share of 1.29p against 1.27p a year ago. Cash and cash equivalents at the period-end stood at £8.2m (January 2016: £19.9m) and the Group has no debt. On the operational front, for DermaPure, the continued focus on adoption and advocacy was rewarded with further Medicare approvals (93% covered) and the Group signed 3 US Group Purchasing Organisations ('GPO') Agreements including top 2 GPO's in US, Premier and Vizient, securing 75% coverage of GPO hospital beds in US. For OrthoPure XT, the Group has submitted initial clinical data for CE mark approval and signed first EU distribution agreement with a commercial roll-out targeted during 2017. Tissue Regenix's CEO, Antony Odell, commented "We believe that the progress we have made across each of our business units and the exciting organic growth opportunities afforded by our broad development pipeline of innovative products and the recently signed GPO contracts means that we are well placed for future growth".

Our view: Tissue Regenix made good operational progress in FY2016. In the US, its wound care business has recorded a revenue growth of +64% and successfully secured expanded Medicare coverage of 93% (for outpatient use) of Medicare beneficiaries, while signing of 3 US GPO Agreements means over 1 million (c.75%) hospital beds in the US is now accessible to the Group's DermaPure. Additionally, Tissue Regenix was added to the Federal Supply Schedule. In the EU, application for CE mark has been submitted for OrthoPure XT (orthopaedic – knee injuries) that the Group is now targeting launch and commercialisation during this year. All positive progress, so only possible cause that triggered c.-5% fall in its share price on Friday was due to its accelerated cash burn (c.£1m per month), which led to a fall in cash balance to just £5.4m at the end of 30 April 2017, which indicates that the Group is only funded through the end of Q3 2017. The Group continue to expect similar level of cash burn for the following 12 months and noted that "further funding is envisaged as the Group seeks to commercialise and develop its products". This has led to an expectation that there will be equity fund raise before the end of Q3 2017 for continue operations. The Group has demonstrated its ability to successfully commercialise its products, whilst also identifying further market entry opportunities. At this moment, however, given anticipated near-term fund raise, we believe there will be limited positive share price movement before this is satisfied. Beaufort therefore downgrade Tissue Regenix from Speculative Buy rating to a Hold in anticipation to seek opportunity at the placing.

 

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 18 minutes ago